Regarding thiazolidinediones, their use in NAFLD is controversial since they can improve IR and decrease lipotoxicity in obese/NAFLD patients, supporting the transcription of Sterol regulatory element-binding protein 1 c (SREBP1c) in the liver, thus enhancing the maintenance of steatosis and production of TGs by liver [311]. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.